trending Market Intelligence /marketintelligence/en/news-insights/trending/ut_cg7_gloklfjvroatulg2 content esgSubNav
In This List

Novo Nordisk to update prescription label of diabetes drug

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery


Novo Nordisk to update prescription label of diabetes drug

Novo Nordisk A/S said it received the U.S. Food and Drug Administration's approval to update the prescription label of its diabetes medicine Tresiba.

The updated label will reflect results from the Devote study, which showed that Tresiba was less likely to cause hypoglycemia in type 2 diabetes patients when compared to Sanofi's Lantus.

Hypoglycemia, commonly caused by medications to treat diabetes, is characterized by abnormally low blood glucose, which results in a variety of symptoms such as clumsiness, trouble talking and, in extreme cases, unconsciousness and death.

The label will also now indicate that Tresiba is just as safe as Lantus in patients at risk of having major adverse cardiovascular events, such as a heart attack or a stroke.